A postbiotic preparation for improving frequent urination, painful urination, dribbling urination and maintaining the prostate, and its preparation method and application

Abstract

The present invention belongs to the field of microorganism and biomedicine technology, and specifically relates to a postbiotic preparation for improving frequent urination, painful urination, dribbling urine, and maintaining prostate, and its preparation method and application. The present invention screens and obtains a strain of Lactobacillus gasseri, and further verifies that the co-fermentation product thereof with Lactobacillus mucosa reuteri and Lactobacillus paracasei presents a synergistic effect. These three lactobacilli promote and cooperate with each other during the co-fermentation process, enhance their respective physiological activities, and thus improve the overall probiotic effect. The co-fermentation product of these three lactobacilli not only has the effect of promoting intestinal health and enhancing immune function, but also can inhibit inflammatory response, improve intestinal environment, and provide all-round health protection for human body. Its synergistic effect provides more comprehensive and effective protection for prostate maintenance, injects new vitality into maintaining prostate health, and therefore has good practical application value.

Description

Technical Field

[0001] The present invention belongs to the technical field of microorganisms and biomedicine, and specifically relates to a postbiotic preparation for improving frequent urination, painful urination, dribbling urination and maintaining the prostate, as well as a preparation method and application thereof. Background Art

[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] As people pay more and more attention to health, prostate health has gradually become a hot topic. The prostate is an important part of male function. It is shaped like a flat chestnut and weighs about 20 grams. It is located between the bladder, urethra and reproductive diaphragm and is hidden deep in the pelvis. It is the largest accessory gland in men and is responsible for important functions such as urine control and semen transmission. Chronic prostatitis is a common and frequently occurring disease in adult men. 30%-34% of men over 35 years old suffer from this disease. Due to long-term congestion of the gland, poor function of the glandular tubules and glands, symptoms such as frequent urination, painful urination, and dribbling urine may occur.

[0004] The incidence of prostate diseases has increased year by year, seriously affecting the quality of life of men. Most men are often ashamed to speak up about reproductive health issues and are afraid to go to the doctor on their own. Therefore, gradually improving reproductive health problems through oral regulators is a better solution. Postbiotics are an emerging concept in the field of microbial preparations and products. They refer to inactivated microorganisms or their fermented components that are beneficial to human health. They have the functions of regulating intestinal health, enhancing immunity, and promoting metabolism. They have the advantages of high safety, strong stability, and convenient storage. They have potential application prospects in the fields of medicine and cosmetics, but there are few reports on their application in prostate care. Summary of the invention

[0005] Based on the above-mentioned deficiencies in the prior art, the present invention provides a postbiotic preparation for improving frequent urination, painful urination, dribbling urination, and maintaining the prostate, and its preparation method and application. Specifically, it has been verified by animal and human experiments that the postbiotic preparation prepared by the present invention has the effect of improving the symptoms of frequent urination, painful urination, and dribbling urination, thereby effectively maintaining the prostate. Based on the above research results, the present invention is completed.

[0006] In order to achieve the above technical objectives, the present invention relates to the following technical solutions:

[0007] One aspect of the present invention provides a strain of Lactobacillus gasseri ( Lactobacillus gasseri) Nice-Lga, deposited in China Center for Type Culture Collection (Address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), the deposit date is September 5, 2024, and its biological deposit number is CCTCC NO: M20241921.

[0008] The second aspect of the present invention provides a postbiotic preparation, which contains at least the above-mentioned Lactobacillus gasseri and / or its fermentation metabolites.

[0009] Furthermore, the postbiotic preparation comprises inactivated Lactobacillus gasseri and its fermentation metabolites, wherein the fermentation metabolites include but are not limited to polysaccharides, polypeptides, amino acids and the like.

[0010] The third aspect of the present invention provides a method for preparing the above-mentioned postbiotic preparation, the preparation method comprising:

[0011] S1. Bacterial activation: Lactobacillus gasseri Lactobacillus gasseri streaking Nice-Lga, Lactobacillus reuteri CICC 6128 and Lactobacillus paracasei CICC 25261 into activation medium to obtain pure strains; inoculating single colonies of Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei into the first culture medium for culturing at 35-37° C. for 12-14 hours;

[0012] S2. Preparation of mixed bacterial solution: Adjust the OD of the bacterial solution of Lactobacillus gasseri, Lactobacillus mucilaginosus and Lactobacillus paracasei in S1 600 values ​​to make them consistent, mixing the Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei to obtain a mixed bacterial solution;

[0013] S3, preparation of mixed seed solution: inoculate the mixed bacterial solution obtained in S2 into the second culture solution at an inoculation amount of 0.5-5% (preferably 0.5%, v / v) and culture at 35-38°C (preferably 37°C) for 12-14 hours to obtain the mixed seed solution;

[0014] S4, multi-strain balanced fermentation: inoculate the mixed seed liquid obtained in S3 into the third culture liquid at an inoculation amount of 2-5% (preferably 3%), and culture at 35-38°C (preferably 37°C) and 40-50 r / min (preferably 40 r / min) for 13-16 hours; after 13-16 hours, keep the stirring speed unchanged, increase the temperature to 60-70°C (preferably 65°C), add glycerol in an amount of 0.1-0.2% (preferably 0.1%) of the fermentation liquid volume to the fermenter, increase the temperature to 90-100°C (preferably 95°C) and maintain for 10-60min (preferably 30 min), and then spray-dry.

[0015] The fourth aspect of the present invention provides the use of the above-mentioned postbiotic preparation in the preparation of products for improving frequent urination, painful urination, dribbling urination, and maintaining the prostate.

[0016] Furthermore, the product for improving frequent urination, painful urination, dribbling urination and maintaining the prostate can be a medicine.

[0017] Beneficial technical effects of one or more of the above technical solutions:

[0018] The above technical scheme screened and obtained a strain of Lactobacillus gasseri, and further verified that the co-fermentation products thereof with Lactobacillus mucilaginosus and Lactobacillus paracasei showed a synergistic effect. The three lactobacilli promoted and cooperated with each other during the co-fermentation process, enhanced their respective physiological activities, and thus improved the overall probiotic effect. As a common probiotic, Lactobacillus gasseri helps to regulate the balance of intestinal flora, resist allergies, enhance immunity, and inhibit the growth of harmful bacteria. The beneficial substances such as butyrate produced by Lactobacillus mucilaginosus can supply energy to intestinal epithelial cells, thereby promoting the growth of intestinal epithelial cells, helping to maintain the acid-base balance of the intestine, and promoting food digestion and absorption. Lactobacillus paracasei is known for its unique antioxidant and anti-inflammatory properties, which can reduce related inflammation and reduce the risk of disease. Therefore, the co-fermentation products of these three lactobacilli not only have the effect of promoting intestinal health and enhancing immune function, but also can inhibit inflammatory reactions, improve the intestinal environment, and provide all-round health protection for the human body. Its synergistic effect provides a more comprehensive and effective guarantee for prostate care, injects new vitality into maintaining prostate health, and therefore has good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0020] Figure 1 This is a diagram showing the HE staining results of the prostate tissue of each group of rats in the experiment to verify the effect of the present invention. DETAILED DESCRIPTION

[0021] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0022] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments of the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0023] In one embodiment of the present invention, a strain of Lactobacillus gasseri ( Lactobacillus gasseri ) Nice-Lga, deposited in the China Center for Type Culture Collection (Address: Wuhan University, Luojia Mountain, Wuchang, Wuhan City, Hubei Province), the deposit date is September 5, 2024, and its biological deposit number is CCTCC NO: M 20241921.

[0024] In another specific embodiment of the present invention, a postbiotic preparation is provided, which contains at least the above-mentioned Lactobacillus gasseri and / or its fermentation metabolite.

[0025] Furthermore, the postbiotic preparation comprises inactivated Lactobacillus gasseri and its fermentation metabolites, wherein the fermentation metabolites include but are not limited to polysaccharides, polypeptides and amino acids.

[0026] In another specific embodiment of the present invention, a method for preparing the above-mentioned postbiotic preparation is provided, and the preparation method comprises:

[0027] S1. Bacterial activation: Lactobacillus gasseri Lactobacillus gasseri streaking Nice-Lga, Lactobacillus reuteri CICC 6128 and Lactobacillus paracasei CICC 25261 into activation medium to obtain pure strains; inoculating single colonies of Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei into the first culture medium for culturing at 35-37° C. for 12-14 hours;

[0028] S2. Preparation of mixed bacterial solution: Adjust the OD of the bacterial solution of Lactobacillus gasseri, Lactobacillus mucilaginosus and Lactobacillus paracasei in S1 600 values ​​to make them consistent, mixing the Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei to obtain a mixed bacterial solution;

[0029] S3, preparation of mixed seed solution: inoculate the mixed bacterial solution obtained in S2 into the second culture solution at an inoculation amount of 1-5% (preferably 3%, v / v) and culture at 35-38°C (preferably 37°C) for 12-14 hours to obtain the mixed seed solution;

[0030] S4, multi-strain balanced fermentation: inoculate the mixed seed liquid obtained in S3 into the third culture liquid at an inoculation amount of 2-5% (preferably 3%), and culture at 35-38°C (preferably 37°C) and 40-50 r / min (preferably 40 r / min) for 13-16 hours; after 13-16 hours, keep the stirring speed unchanged, increase the temperature to 60-70°C (preferably 65°C), add glycerol in an amount of 0.1-0.2% (preferably 0.1%) of the fermentation liquid volume to the fermenter, increase the temperature to 90-100°C (preferably 95°C) and maintain for 10-60min (preferably 30 min), and then spray-dry.

[0031] The activation culture medium is composed of: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.1-0.3% yeast extract powder, 0.05-0.2% sodium acetate, 0.05-0.2% potassium dihydrogen phosphate, 0.15-0.2% agar powder, 0.01-0.02% Tween 80, and the pH is adjusted to 6.5.

[0032] The first culture solution is composed of: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.01%-0.02% peptidoglycan, 0.1-0.5% yeast extract powder, 0.1-0.5% sodium acetate, 0.1-0.3% potassium dihydrogen phosphate, 0.2-0.5% lycopene, and the pH is adjusted to 6.5.

[0033] The second culture solution is composed of: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.1-0.3% yeast extract powder, 0.1-0.3% sodium acetate, 0.1-0.3% potassium dihydrogen phosphate, 0.2-0.5% lycopene, and the pH is adjusted to 6.5.

[0034] The third culture solution is composed of: 1-3% yeast peptone, 0.1-1% beef extract, 0.1-1% yeast extract powder, 1-5% fructo-oligosaccharide, 0.5-2% yeast powder, 0.1-0.5% Tween-80, 0.2-0.5% lycopene, 1-5% yam starch, 0.1-0.5% sodium acetate, 0.1-0.5% potassium dihydrogen phosphate, 1-5% isomaltooligosaccharide, 1-5% water-soluble starch, 0.1-1% tyrosine, 0.1-0.5% polyether defoamer, pH 6.5.

[0035] Provided is the use of the above-mentioned postbiotic preparation in preparing products for improving frequent urination, painful urination, dribbling urination and maintaining the prostate.

[0036] The product may be a pharmaceutical product.

[0037] The present invention has verified through animal experiments that the above-mentioned postbiotic preparation can effectively reduce the content of serum inflammatory factors in rats with prostate inflammation model and improve the symptoms of prostate hyperplasia. At the same time, it has been proved through small-scale population experiments that it can improve symptoms such as frequent urination, urgency, pain when urinating, and dribbling urine.

[0038] More specifically, the drug may further include at least one other inactive pharmaceutical ingredient.

[0039] The inactive ingredients of the drug may be carriers, excipients and diluents commonly used in pharmacy, etc. Moreover, according to the usual method, the drug may be prepared into oral preparations such as powders, granules, suspensions, emulsions, syrups, sprays, etc.

[0040] The non-drug active ingredients such as carriers, excipients and diluents that may be included are well known in the art, and those skilled in the art can determine whether they meet clinical standards.

[0041] In another specific embodiment of the present invention, the carrier, excipient and diluent include but are not limited to lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil.

[0042] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. Lactobacillus reuteri CICC 6128 and Lactobacillus paracasei CICC 25261 were purchased from the China Industrial Microbial Culture Collection Administration Center.

[0043] In each embodiment, the composition of the activation medium is: yeast peptone 0.2%, beef extract 0.3%, yeast extract powder 0.2%, sodium acetate 0.05%, potassium dihydrogen phosphate 0.05%, agar powder 0.15%, Tween 80 0.01%, and the pH is adjusted to 6.5.

[0044] The composition of the first culture medium is: 0.2% yeast peptone, 0.5% beef extract, 0.02% peptidoglycan, 0.2% yeast extract powder, 0.2% sodium acetate, 0.2% potassium dihydrogen phosphate, 0.3% lycopene, and the pH is adjusted to 6.5.

[0045] The composition of the second culture medium is: 0.2% yeast peptone, 0.5% beef extract, 0.2% yeast extract powder, 0.2% sodium acetate, 0.2% potassium dihydrogen phosphate, 0.2% lycopene, and the pH is adjusted to 6.5.

[0046] The composition of the third culture solution is as follows: 2% yeast peptone, 0.5% beef extract, 0.5% yeast extract powder, 3% oligofructose, 1% yeast powder, 0.2% Tween-80, 0.2% lycopene, 1% yam starch, 0.1% sodium acetate, 0.2% potassium dihydrogen phosphate, 2% isomaltooligosaccharide, 2% water-soluble starch, 0.2% tyrosine, 0.1% polyether defoamer, pH 6.5.

[0047] The “%” of each component in each culture (base) solution is the mass volume percentage, the unit is g / mL.

[0048] Example 1

[0049] Lactobacillus gasseri Lactobacillus gasseri Nice-Lga, Lactobacillus reuteri CICC 6128 and Lactobacillus paracasei CICC 25261 were streaked into the activation medium to obtain pure strains; single colonies of Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei were inoculated into the first culture medium for culturing at 37°C for 12 hours; the OD of the bacterial cultures of Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei were adjusted 600 The value is 0.5, and then Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei are mixed in a volume ratio of 1:1:1 to obtain a mixed bacterial solution; according to the inoculation amount of 3% ( v / v ) Inoculate the mixed bacterial solution into the second culture solution and culture it at 37°C for 14 hours to obtain a mixed seed solution;

[0050] The mixed seed solution was inoculated into a fermenter containing the third culture solution at an inoculation rate of 5%, and cultured at 37 °C and 40 r / min for 16 hours. After 16 hours, the stirring speed was kept unchanged, the temperature was increased to 65 °C, 0.1% glycerol by volume of the fermentation solution was added to the fermenter, the temperature was increased to 95 °C and maintained for 30 min, and then spray-dried.

[0051] Example 2

[0052] Lactobacillus gasseri Lactobacillus gasseri Nice-Lga and Lactobacillus reuteri CICC 6128 were streaked into the activation medium to obtain pure strains; single colonies of Lactobacillus gasseri and Lactobacillus reuteri were inoculated into the first culture medium for cultivation at 37°C for 12 hours; the OD of the bacterial cultures of Lactobacillus gasseri and Lactobacillus reuteri was adjusted 600 The value is 0.5, and then Lactobacillus gasseri and Lactobacillus mucilaginosus reuteri are mixed in a ratio of 1:1 to obtain a mixed bacterial solution;

[0053] The mixed bacterial solution was inoculated into the second culture solution at an inoculum amount of 3%, and the mixed seed solution was obtained by static culture at 37°C for 14 hours;

[0054] The mixed seed solution was inoculated into a fermenter containing the third culture solution at an inoculation rate of 5%, and cultured at 37 °C and 40 r / min for 16 hours; after 16 hours, the stirring speed remained unchanged, the temperature was increased to 65 °C, 0.1% glycerol by volume of the fermentation solution was added to the fermenter, the temperature was increased to 95 °C and maintained for 30 min, and then spray-dried.

[0055] Example 3

[0056] Lactobacillus gasseri Lactobacillus gasseri Nice-Lga was streaked into the activation medium to obtain a pure strain; a single colony of Lactobacillus gasseri was inoculated into the first culture medium for cultivation, and cultured at 37°C for 12 hours to obtain a seed solution; the OD of the Lactobacillus gasseri seed solution was adjusted 600 The value is 0.5, and the bacterial liquid is inoculated into the second culture liquid at an inoculum amount of 3%, and the seed liquid before fermentation is obtained by static culture at 37 ℃ for 14 hours;

[0057] The pre-fermentation seed liquid was inoculated into a fermenter containing the third culture medium at an inoculation rate of 5%, and cultured at 37 °C and 40 r / min for 16 hours; after 16 hours, the stirring speed was kept unchanged, the temperature was increased to 65 °C, 0.1% glycerol by volume of the fermentation liquid was added to the fermenter, the temperature was increased to 95 °C and maintained for 30 min, and then spray-dried.

[0058] Effect verification

[0059] 1. Rat Experiment

[0060] 55 male 8-week-old healthy SPF SD rats weighing (200±50)g were randomly selected as the blank group, and the remaining 45 were used as the modeling group. They were given intraperitoneal injection of testosterone propionate 5 mg / kg (dissolved in sterile olive oil at a ratio of 1:1), once a day, weighed every Friday, and the dosage was adjusted according to the body weight for 4 consecutive weeks. On the 28th day of modeling, 5 rats were fasted for 24 hours after the last administration. The blank group and the modeling group were each selected, and the prostate tissue was removed for hematoxylin-eosin (HE) staining. Under the microscope, the blank group showed that the prostate glands were closely arranged and there was no obvious hyperplasia of the stroma; under the microscope, the prostate glands in the modeling group hyperplasia to varying degrees, and the modeling (prostate hyperplasia (BPH) rats) was clearly successful. The 40 modeling group rats were randomly divided into the model group, Example 1 group, Example 2 group and Example 3 group, with 10 rats in each group. The blank group and the model group were gavaged with 0.9% sodium chloride solution at 1 mL / 100mg, once a day. The postbiotic group was gavaged with a suspension at a concentration of 75 mg / kg, once a day, for 4 consecutive weeks. Each group was weighed and recorded 24 hours after the last administration. After intraperitoneal anesthesia, blood was collected from the abdominal aorta, and ELISA was used to detect the contents of serum interleukin (IL)-6, tumor necrosis factor (TNF)-α, serum testosterone (T), dihydrotestosterone (DHT), estradiol (E2), serum epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF). The prostate tissue of each group was removed, rinsed with physiological saline, and the surface moisture of the tissue was absorbed by filter paper. The wet weight was weighed, the prostate weight of the rat and the body weight of the rat were recorded, and the PI of each group was calculated. PI=prostate weight (mg) / body weight (g). Rats in the model group and Example 1 group were randomly selected, and the prostate tissue morphology was observed by HE staining.

[0061] Compared with the PI (1.5±0.2)% of the control group, the PI (3.4±0.6)% of the model group was significantly increased. Compared with the model group, the PI (1.7±0.4)% of the Example 1 group was significantly decreased. There was no significant change in the PI (3.3±0.8)% of the Example 2 group and the PI (3.5±0.8)% of the Example 3 group.

[0062] Compared with the control group, the serum VEGF and EGF levels in the model group were significantly increased, and compared with the model group, the Example 1 group was significantly decreased, and the regulatory effect of postbiotics on EGF was obvious. Compared with the control group, the serum TNF-α and IL-6 levels in the model group were significantly increased, and compared with the model group, the Example 1 group was significantly decreased, and the improvement effect of postbiotics was the most obvious. Compared with the control group, the serum T, DHT and E2 levels in the model group were significantly increased, and compared with the model group, the Example 1 group was significantly improved. It can be seen from the results that postbiotics have a significant improvement effect on BPH rats.

[0063] Table 1. Levels of inflammatory factors, epidermal growth factor and sex hormones in rats in each group

[0064]

[0065] According to the results of HE staining of prostate tissue, the glands in the blank group were full and regular, and the matrix tissue was loose; the glands in the model group were irregular, the glandular epithelial cells proliferated, fibrous tissue hyperplasia appeared in the matrix, and there was inflammatory cell infiltration; the glands in the postbiotic group were regular, without obvious glandular epithelial hyperplasia, a small amount of fibrous tissue hyperplasia in the matrix, and a small amount of inflammatory cell infiltration, indicating that postbiotics have a significant therapeutic effect on prostate hyperplasia and inflammation.

[0066] 2. Small-scale population experiments

[0067] 30 men aged 40-70 years old, who were willing to participate in the experiment and were able to complete the questionnaire and record, and who were suffering from prostate problems were included in the experimental group. 600 mg of postbiotics (the product prepared in Example 1) were taken orally on an empty stomach every morning for 4 weeks. Questionnaires were conducted before and after taking. The original eating habits were not changed during the drinking period, and the diet was normal.

[0068] Before taking the medicine, 98% of the people said they had prostate problems such as frequent urination and urgent urination. After taking Hou Shengyuan, 100% of the people said there was a significant improvement, including frequent urination, urgent urination, painful urination, and dribbling urination.

[0069] Table 2. Statistics of postbiotic population trials for improving prostate problems

[0070]

[0071] Finally, it should be noted that the above is only a preferred embodiment of the present invention and is not intended to limit the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, it is still possible for those skilled in the art to modify the technical solutions described in the aforementioned embodiments, or to perform equivalent replacements on parts thereof. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention. Although the above describes the specific implementation methods of the present invention, it is not intended to limit the protection scope of the present invention. Those skilled in the art should understand that, based on the technical solution of the present invention, various modifications or deformations that can be made by those skilled in the art without creative labor are still within the protection scope of the present invention.

Claims

1. A postbiotic preparation, characterized in that It contains Lactobacillus gasseri ( Lactobacillus gasseri )Nice-Lga, Lactobacillus reuteri( Limosilactobacillus reuteri ) CICC 6128 and Lactobacillus paracasei ( Lacticaseibacillus paracasei )CICC 25261; Wherein, the Lactobacillus gasseri ( Lactobacillus gasseri ) Nice-Lga, deposited in China Center for Type Culture Collection, the deposit date is September 5, 2024, and its deposit number is CCTCC NO: M 20241921.

2. The method for preparing the postbiotic preparation according to claim 1, characterized in that: The preparation method comprises: S1, bacterial activation: the Lactobacillus gasseri ( Lactobacillus gasseri )Nice-Lga, Lactobacillus reuteri( Limosilactobacillus reuteri ) CICC 6128 and Lactobacillus paracasei ( Lacticaseibacillus paracasei ) streaking CICC 25261 into the activation medium to obtain a pure strain; inoculating single colonies of Lactobacillus gasseri, Lactobacillus mucilaginosus reuteri and Lactobacillus paracasei into the first culture medium for culturing at 35-37°C for 12-14 hours; S2. Preparation of mixed bacterial solution: Adjust the OD of the bacterial solution of Lactobacillus gasseri, Lactobacillus mucilaginosus and Lactobacillus paracasei in S1 600 values ​​to make them consistent, mixing the Lactobacillus gasseri, Lactobacillus reuteri and Lactobacillus paracasei to obtain a mixed bacterial solution; S3, preparation of mixed seed solution: inoculate the mixed bacterial solution obtained in S2 into the second culture solution at an inoculation rate of 1-5%, and culture at 35-38° C. for 12-14 hours to obtain the mixed seed solution; S4, multi-strain balanced fermentation: inoculate the mixed seed solution obtained in S3 into the third culture solution at an inoculum size of 2-5%, and culture at 35-38°C, 40-50 r / min for 13-16 hours; after 13-16 hours, keep the stirring speed unchanged, increase the temperature to 60-70°C, add glycerol (0.1-0.2% of the volume of the fermentation solution) to the fermenter, increase the temperature to 90-100°C, maintain for 10-60 min, and then spray-dry.

3. The preparation method according to claim 2, characterized in that: In the step S1, The activation culture medium is composed of: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.1-0.3% yeast extract powder, 0.05-0.2% sodium acetate, 0.05-0.2% potassium dihydrogen phosphate, 0.15-0.2% agar powder and 0.01-0.02% Tween 80, and the pH is adjusted to 6.5; the "%" of the components in the activation culture medium is the mass volume percentage, and the unit is g / mL.

4. The preparation method according to claim 2, characterized in that: In the step S2, The composition of the first culture solution is as follows: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.01%-0.02% peptidoglycan, 0.1-0.5% yeast extract powder, 0.1-0.5% sodium acetate, 0.1-0.3% potassium dihydrogen phosphate and 0.2-0.5% lycopene, and the pH is adjusted to 6.5; the "%" of the components in the first culture solution is the mass volume percentage, and the unit is g / mL.

5. The preparation method according to claim 2, characterized in that: In the step S3, The composition of the second culture solution is as follows: 0.1-0.3% yeast peptone, 0.3-1.0% beef extract, 0.1-0.3% yeast extract powder, 0.1-0.3% sodium acetate, 0.1-0.3% potassium dihydrogen phosphate and 0.2-0.5% lycopene, and the pH is adjusted to 6.5; the "%" of the components in the second culture solution is the mass volume percentage, and the unit is g / mL.

6. The preparation method according to claim 2, characterized in that: In step S4, the composition of the third culture solution is as follows: 1-3% yeast peptone, 0.1-1% beef extract, 0.1-1% yeast extract powder, 1-5% fructo-oligosaccharide, 0.5-2% yeast powder, 0.1-0.5% Tween-80, 0.2-0.5% lycopene, 1-5% yam starch, 0.1-0.5% sodium acetate, 0.1-0.5% potassium dihydrogen phosphate, 1-5% isomaltooligosaccharide, 1-5% water-soluble starch, 0.1-1% tyrosine and 0.1-0.5% polyether defoamer, pH 6.5; the composition "%" in the third culture solution is mass volume percentage, in g / mL.

7. Use of the postbiotic preparation according to claim 1 in the preparation of a medicine for treating prostatic hyperplasia.

Images